CTRI/2021/05/033750已完成未知
Proof of concept study to evaluate the safety and effectiveness of Favipiravir DPI as an intervention in subjects with SARS-CoV-2 Infection. - Nil
SAVA Healthcare Ltd0 个研究点目标入组 60 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1.Age -18- 60 years (Both sex)
- •2.Confirmed COVID 19 patient with positive RT-PCR
- •3.Mild symptomatic or asymptomatic patients having no signs of severe disease (NEWS score <=6) and no comorbidity at screening
- •4.Subject willing to provide consent and follow up for study duration
排除标准
- •1.Patients with compromised immunity, autoimmune disease or self-reports HIV or syphilis infection
- •2.Proves to be unfit for the study as per the investigatorâ??s discretion
- •3.Pregnant or lactating women
- •4.Requiring supplemental oxygen and ICU admission at screening
- •5.Comorbidity at screening and which in investigator discretion finds subject not suitable for the trial participation
研究者
相似试验
招募中
1 期
Propofol on Trial for Headaches in the Emergency Department SettingACTRN12617000345381Dr Erik Wood30
进行中（未招募）
1 期
Survival Prolongation by Rationale Innovative GenomicsPatients with advanced/metastatic non-small cell lung cancer (NSCLC) with no documented targetable alterations (EGFR mutation, ALK translocation, ROS1 mutation if available or MET exon 14 skipping mutation if available)EUCTR2017-001455-32-FRWorldwide Innovative Network Association130
进行中（未招募）
1 期
Survival Prolongation by Rationale Innovative GenomicsPatients with advanced/metastatic non-small cell lung cancer (NSCLC) with no documented targetable alterations (EGFR mutation, ALK translocation, ROS1 mutation if available or MET exon 14 skipping mutation if available)EUCTR2017-001455-32-ESWorldwide Innovative Network Association130
已完成
不适用
The objective of the project will be to assess whether this technology(PPIUCD inserter) iseffective and if its use can be recommended to other women in India and around the world.Post Partum Family Planning methodCTRI/2015/03/005619SAIDUnited States Agency for International Development70
已完成
2 期
A study of the effect of oral LAT8881 on acute migraine headacheACTRN12619001369112ateral Pharma Pty Ltd21